title: Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas.
abstract: The somatostatin analog octreotide was administered prior to transsphenoidal surgery in three patients with tumors that extended to the suprasellar space and one side of the cavernous sinus. Octreotide, 100 micrograms twice a day, was subcutaneously injected for 2 weeks. Octreotide administration reduced the serum growth hormone (GH) levels in these patients from 82 to 22 ng/ml, from 148 to 12 ng/ml, and from 129 to 9 ng/ml. The tumor size shrank by about 50%, and the suprasellar extension disappeared in two patients. The main tumor was sharply dissected from the normal pituitary gland at surgery. Intracavernous portions were removed using a curette. Postoperatively, GH levels were less than 5 ng/ml in two patients, and 8.5 ng/ml in one patient. Follow-up magnetic resonance imaging revealed a small residual tumor in one side of the cavernous sinus in all patients. Follow-up GH levels were less than 5 ng/ml in one patient, and less than 2 ng/ml in two patients treated with bromocriptine. Preoperative administration of octreotide for 2 weeks reduced tumor volume and allowed near-total surgical resection of invasive macroadenomas without compromising the treatment course. Residual tumor due to intracavernous extension can be managed with bromocriptine or gamma knife radiosurgery.
authors.affiliation: Department of Neurosurgery, Nagoya University School of Medicine.
authors.forename: E
authors.initials: E
authors.lastname: Tachibana
authors.forename: K
authors.initials: K
authors.lastname: Saito
authors.forename: J
authors.initials: J
authors.lastname: Yoshida
mesh_terms: D000172:Acromegaly / Q000209:etiology; D000236:Adenoma / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D019635:Neurosurgical Procedures / Q000379:methods*; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D013101:Sphenoid Sinus / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013006:Growth Hormone; D015282:Octreotide